ConductScience.org, home

Paper40936993

Risk factors of hemoptysis recurrence after bronchial artery embolization and patient feedbacks.

Yang B and 3 others. Turk Gogus Kalp Damar Cerrahisi Derg, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Risk factors of hemoptysis recurrence after bronchial artery embolization and patient feedbacks. Papers, record 40936993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40936993

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Risk factors of hemoptysis recurrence after bronchial artery embolization and patient feedbacks.
PubMed
Journal
Turk Gogus Kalp Damar Cerrahisi Derg
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2025-09-15
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120058006Radiological management of hemoptysis: a comprehensive review of diagnostic imaging and bronchial arterial embolization.Cardiovasc Intervent Radiol2010https://conductscience.org/library/papers/20058006PubMed
221257863Bronchial and nonbronchial systemic artery embolization in patients with major hemoptysis: safety and efficacy of N-butyl cyanoacrylate.AJR Am J Roentgenol2011https://conductscience.org/library/papers/21257863PubMed
333598631Bronchial Artery Embolization in Life-Threatening Hemoptysis: Outcome and Predictive Factors.J Belg Soc Radiol2021https://conductscience.org/library/papers/33598631PubMed
425960838A retrospective analysis of 334 cases of hemoptysis treated by bronchial artery embolization.Oman Med J2015https://conductscience.org/library/papers/25960838PubMed
529477622Safety and Efficacy of Repeat Embolization for Recurrent Hemoptysis: A 16-Year Retrospective Study Including 223 Patients.J Vasc Interv Radiol2018https://conductscience.org/library/papers/29477622PubMed
618681960Approach to diagnosis and pathological examination in bronchial Dieulafoy disease: a case series.Respir Res2008https://conductscience.org/library/papers/18681960PubMed
725053662Bronchial artery embolization for massive hemoptysis: long-term follow-up.Asian Cardiovasc Thorac Ann2015https://conductscience.org/library/papers/25053662PubMed
831374211Managing Massive Hemoptysis.Chest2020https://conductscience.org/library/papers/31374211PubMed
933312029Bronchial Artery Embolization, an Increasingly Used Method for Hemoptysis; Treatment and Avoidance.Sisli Etfal Hastan Tip Bul2020https://conductscience.org/library/papers/33312029PubMed
1017468904Bronchial artery and systemic artery embolization in the management of primary lung cancer patients with hemoptysis.Cardiovasc Intervent Radiol2007https://conductscience.org/library/papers/17468904PubMed
1124252773Results of bronchial artery embolization for the treatment of hemoptysis caused by neoplasm.J Vasc Interv Radiol2014https://conductscience.org/library/papers/24252773PubMed
1229067512Bronchial Artery Embolization with Large Sized (700-900 µm) Tris-acryl Microspheres (Embosphere) for Massive Hemoptysis: Long-Term Results (Clinical Research).Cardiovasc Intervent Radiol2018https://conductscience.org/library/papers/29067512PubMed
1321444351Nine-year single-center experience with transcatheter arterial embolization for hemoptysis: medium-term outcomes.Vasc Endovascular Surg2011https://conductscience.org/library/papers/21444351PubMed
1438658883Embosphere microspheres size for bronchial artery embolization in patients with hemoptysis caused by bronchiectasis: a retrospective comparative analysis of 500-750 versus 700-900 μm microspheres.BMC Pulm Med2024https://conductscience.org/library/papers/38658883PubMed
1516418239Multi-detector row CT of hemoptysis.Radiographics2006https://conductscience.org/library/papers/16418239PubMed
1628703105Bronchial artery embolization in hemoptysis: a systematic review.Diagn Interv Radiol2017https://conductscience.org/library/papers/28703105PubMed
1729073778Bronchial artery embolization: first-line option for managing massive hemoptysis.Asian Cardiovasc Thorac Ann2017https://conductscience.org/library/papers/29073778PubMed
1832370959ACR Appropriateness Criteria® Hemoptysis.J Am Coll Radiol2020https://conductscience.org/library/papers/32370959PubMed
1923801773Bronchial artery embolization to control hemoptysis: comparison of N-butyl-2-cyanoacrylate and polyvinyl alcohol particles.Radiology2013https://conductscience.org/library/papers/23801773PubMed
2029196112Long-term outcomes and prognostic factors in patients with mild hemoptysis.Am J Emerg Med2018https://conductscience.org/library/papers/29196112PubMed

See all 26 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42414635Predictors of Recurrence Following Bronchial Artery Embolisation (BAE) for Haemoptysis: A Systematic Review and Evidence Synthesis Analyses Using SWiM Guidelines.Cardiovasc Intervent Radiol2026https://conductscience.org/library/papers/42414635PubMed
42223216Comment on: Risk factors of hemoptysis recurrence after BAE.Turk Gogus Kalp Damar Cerrahisi Derg2026https://conductscience.org/library/papers/42223216PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40936993

GET https://conductscience.org/api/papers/v1/40936993/references?page=2